These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10096254)

  • 1. Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases.
    Re GG; Hazen-Martin DJ; El Bahtimi R; Brownlee NA; Willingham MC; Garvin AJ
    Int J Cancer; 1999 Apr; 84(2):192-200. PubMed ID: 10096254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
    Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
    Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma.
    Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Van den Heuvel MM; Noordzij MA; Nijman RJ; Soliman EH; van Steenbrugge GJ
    Br J Cancer; 2001 Nov; 85(10):1557-63. PubMed ID: 11720445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
    Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
    Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.
    Mayo MW; Wang CY; Drouin SS; Madrid LV; Marshall AF; Reed JC; Weissman BE; Baldwin AS
    EMBO J; 1999 Jul; 18(14):3990-4003. PubMed ID: 10406804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotype, mRNA expression, and gene structure of p53 in Wilms' tumors.
    el Bahtimi R; Hazen-Martin DJ; Re GG; Willingham MC; Garvin AJ
    Mod Pathol; 1996 Mar; 9(3):238-44. PubMed ID: 8685221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinctive properties of an anaplastic Wilms' tumor and its associated epithelial cell line.
    Hazen-Martin DJ; Re GG; Garvin AJ; Sens DA
    Am J Pathol; 1994 May; 144(5):1023-34. PubMed ID: 8178926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of nuclear unrest and p53 immunostaining in Wilms' tumor.
    Salama A; Kamel A
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):31-9. PubMed ID: 22099934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
    Lahoti C; Thorner P; Malkin D; Yeger H
    Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
    Cheah PL; Looi LM; Chan LL
    Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center.
    Zuppan CW; Beckwith JB; Luckey DW
    Hum Pathol; 1988 Oct; 19(10):1199-209. PubMed ID: 2844645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
    Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
    Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptotic protein expression in favorable-histology Wilms tumor correlates with tumor recurrence.
    Agarwal S; Iyer VK; Agarwala S; Mathur SR; Aron M; Datta Gupta S; Verma K
    Pediatr Surg Int; 2011 Mar; 27(3):303-8. PubMed ID: 20963425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaplastic Wilms' tumor: clinical and pathologic studies.
    Bonadio JF; Storer B; Norkool P; Farewell VT; Beckwith JB; D'Angio GJ
    J Clin Oncol; 1985 Apr; 3(4):513-20. PubMed ID: 2984344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of apoptosis, cell proliferation, and drug resistance genes in pediatric Wilms' tumors.
    Ramachandran C; Melnick SJ; Escalon E; Jhabvala P; Khatib Z; Alamo A; Smith S
    Anticancer Res; 2000; 20(5C):3759-65. PubMed ID: 11268451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations.
    Bardeesy N; Beckwith JB; Pelletier J
    Cancer Res; 1995 Jan; 55(2):215-9. PubMed ID: 7812946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of E2F3 expression with clinicopathological features of Wilms' tumors.
    An Q; Wang Y; An R; Li Y; Yao T; Zhai B; Sun X
    J Pediatr Surg; 2013 Nov; 48(11):2187-93. PubMed ID: 24210184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and localization of HGF and met in Wilms' tumours.
    Alami J; Williams BR; Yeger H
    J Pathol; 2002 Jan; 196(1):76-84. PubMed ID: 11748645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.